questionText: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of the removal of access to a CAR-T therapy for mantle cell lymphoma on patients; and if his Department will consider learnings from other health systems that have provided access.
answerText: The National Institute for Health and Care Excellence (NICE) is re-evaluating brexucabtagene autoleucel following managed access through the Cancer Drugs Fund to determine whether it should be recommended for routine National Health Service funding. NICE’...
heading: Blood Cancer: Immunotherapy